v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
During the quarter ended December 31, 2024, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated trading plans intended to satisfy Rule 10b5-1(c), except as set forth in the following table:
NameTitleAdoption or Termination DatePlan Start DatePlan End Date
Shares
Vesting and
Subject to
Sell-To-
Cover (1)
Other
Shares
Being Sold
(Subject to
Certain
Conditions)
James HamiltonChief of Discovery and Translational Medicine
Terminated on 10/18/24
12/4/202411/28/2025n/a30,000
(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
James Hamilton [Member]  
Trading Arrangements, by Individual  
Name James Hamilton
Title Chief of Discovery and Translational Medicine
Rule 10b5-1 Arrangement Terminated true
Termination Date 10/18/24
Arrangement Duration 359 days
Aggregate Available 30,000